Press Releases

Date Title and Summary
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , June 6, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Sandeep Chalke , the company's new senior vice president, chief commercial officer. As a material inducement to Mr.
Toggle Summary Accuray and Limbus AI Inc. Partner to Leverage Limbus' Innovative AI-driven Technology to Enhance Accuray Adaptive Radiotherapy Solutions
Partnership will Enable Accuray to Use Limbus' Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency SUNNYVALE, Calif. and SASKATCHEWAN, Canada , June 2, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc.
Toggle Summary Accuray Appoints Sandeep Chalke as SVP, Chief Commercial Officer
SUNNYVALE, Calif. , May 17, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Sandeep Chalke has joined the company as senior vice president, chief commercial officer effective May 16, 2022 . Mr. Chalke will have responsibility for the global commercial, product
Toggle Summary New Data Presented at ESTRO 2022 Reinforce Benefits of Accuray CyberKnife® and TomoTherapy® Platforms Across a Range of Indications and Complexities
More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies SUNNYVALE, Calif. , May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife®  and
Toggle Summary Accuray ClearRT™ Helical Fan-Beam kVCT Imaging Wins "Best New Technology Solution for Oncology" MedTech Breakthrough Award
Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies SUNNYVALE, Calif. , May 5, 2022 /PRNewswire/ -- Accuray Incorporated  (NASDAQ: ARAY) announced today that its ClearRT ™ helical fan-beam kVCT imaging capability for the Radixact®  System has been
Toggle Summary Accuray Reports Fiscal 2022 Third Quarter Financial Results
SUNNYVALE, Calif. , April 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter of fiscal 2022 ended March 31, 2022 .     Third Quarter Fiscal 2022 Summary Gross orders of $88.6 million , an increase of 1 percent compared to the prior
Toggle Summary Accuray Announces Suzanne Winter, President, Promoted to President and CEO; Joshua Levine Will Retire as CEO and Board Member
Accuray Also Announces Chief Financial Officer, Ali Pervaiz SUNNYVALE, Calif. , April 27, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Suzanne Winter , President, will succeed Joshua Levine as the company's Chief Executive Officer, effective July 1, 2022 .     Mr.
Toggle Summary Owner of Arkansas Derby Winner Named Horse After the Life-Changing Accuray CyberKnife® Radiation Therapy Technology Used to Treat His Cancer
SUNNYVALE, Calif. , April 21, 2022 /PRNewswire/ -- When Al Gold , the owner of the Arkansas Derby winner Cyberknife, received a diagnosis of prostate cancer, he was determined to find a potential cure for his disease while minimizing the impact of treatment on his daily life. Mr.
Toggle Summary Accuray to Report Third Quarter Fiscal 2022 Financial Results on April 27, 2022
SUNNYVALE, Calif. , April 13, 2022 /PRNewswire/ -- Accuray Incorporated  (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2022, ended March 31, 2022, after the market close on April 27, 2022. Management will host a conference call to review the results at 1:30 p.m.
Toggle Summary 10-Year Data Shows Accuray CyberKnife® System Provides Long-Lasting Relief of the Excruciating Pain Caused by Trigeminal Neuralgia
Study Abstract Recognized as Best Clinical Abstract at 2022 Radiosurgical Society Meeting SUNNYVALE, Calif. , March 31, 2022 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that long-term follow-up data from a study of men and women with trigeminal neuralgia (TN) showed 72

*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at and on the SEC's website at